← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
26	26 Cogent Biosciences COGT $4.88B	323	+18	+6%	$7.5B
27	27 Iovance Biotherapeutics IOVA $6.44B	293	+7	+2%	$1.19B
28	28 DELISTED Nuvalent NUVL	292	+27	+10%	$9.29B
29	29 Genmab GMAB $22.7B	291	+16	+6%	$2.81B
30	30 IDEAYA Biosciences IDYA $3.27B	285	+31	+12%	$3.8B
31	31 BeOne Medicines Ltd ONC $39.8B	283	+1	+0.4%	$9.95B
32	32 BioNTech BNTX $22.3B	282	+10	+4%	$4.36B
33	33 Celcuity CELC $2.93B	273	-3	-1%	$5.95B
34	34 NeoGenomics NEO $2.17B	266	+13	+5%	$2.11B
35	35 Geron GERN $765M	260	+4	+2%	$610M
36	36 Relay Therapeutics RLAY $3.74B	259	+15	+6%	$4.58B
37	37 Erasca ERAS $5.14B	256	+31	+14%	$5.13B
38	38 Tango Therapeutics TNGX $3.74B	248	+54	+28%	$6.6B
39	39 Caris Life Sciences CAI $8.55B	247	+45	+22%	$2.75B
40	40 Nuvation Bio NUVB $1.64B	244	+11	+5%	$1.33B
41	41 Summit Therapeutics SMMT $12.1B	242	+20	+9%	$1.98B
42	42 Syndax Pharmaceuticals SNDX $1.21B	242	-5	-2%	$2.36B
43	43 Vir Biotechnology VIR $1.76B	237	-15	-6%	$1.49B
44	44 Arcus Biosciences RCUS $2.87B	231	+20	+9%	$3.78B
45	45 Schrodinger SDGR $1.87B	231	+2	+0.9%	$1.05B
46	46 CG Oncology CGON $5.48B	227	-6	-3%	$6.66B
47	47 Opko Health OPK $1.02B	222	-14	-6%	$303M
48	48 Kura Oncology KURA $855M	221	-1	-0.5%	$953M
49	49 Legend Biotech LEGN $3.7B	219	+29	+15%	$2.98B
50	50 Compass Therapeutics CMPX $158M	215	+14	+7%	$363M